Navigation Links
Potential for Adult Stem Cells to Repair Hearts Damaged Investigated

at are under investigation in this trial.

The baseline frequency and severity of anginal episodes are established as a first step for all study subjects. Next, all subjects receive a series of subcutaneous injections (needle shots, typically delivered under the skin in the arm, thigh or abdomen) of a commercially produced protein (granulocyte colony stimulating factor). The protein helps to release CD34+ stem cells (also known as endothelial progenitor cells) from a subject’s bone marrow into the bloodstream.

Then, investigators use a cell separation system, similar to the automated systems that are used with people who donate specific blood components such as platelets or red blood cells, to collect from the subject’s bloodstream, an enriched preparation of cells that contain CD34+ stem cells. When this process, known as apheresis, is complete, technologists further process the collected stem cells with Baxter’s ISOLEX 300i Magnetic Cell Selection System, currently approved for use with cancer patients, to select the subject’s CD34+ stem cells for use in this investigational therapy.

Schaer then uses a catheter-based, non-surgical system to map the patient’s heart three-dimensionally to identify the damaged areas into which the stem cells would be injected. "This targeted approach increases the treatment's effectiveness by delivering the stem cells exactly where they are needed." Schaer uses the Johnson & Johnson’s NOGA XP Cardiac Navigation System to identify Ischemic but viable regions of the heart as targets for cell delivery. The researchers then use a special investigational catheter that functions like a "global positioning system" to precisely deliver CD34+ cells, or placebo, into the areas of the heart that have been identified as having poor blood flow.

Subjects are randomly selected to receive either one of two dosing levels of CD34+ stem cells, or placebo. Rush researchers will conduct follow-up examinations for 12
'"/>




Page: 1 2 3

Related medicine news :

1. Potential New Cancer Gene Identified
2. Lack of Smell And Its Potential Risks
3. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
4. The Potential Of Cadaver Transplantation Programme In India
5. Another Potential Of Stem Cells Discovered: Used For Growing Cartilage
6. Yoga Guru Ramdev Invited to Tap Ayurveda Potential by Jharkhand Govt
7. A Protein In Yoghurt Has The Potential To Fight E. coli
8. Gold Therapy- A Potential Treatment For Autoimmune Diseases
9. Whirlpool Bath Tubs Contain Potentially Lethal Bacterial Strains
10. Potential Benefits Of New Nanotechnology
11. Hormone Can Foretell Presence Of Potentially Fatal Pulmonary Hypertension

Post Your Comments:
(Date:12/3/2009)...sue of Deutsches rzteblatt International contain...xperience with the novel influenza A virus (H1N1/0...t of the pandemic. Ralf Winzer and his coauthors f...ely evaluated data from a large clinical cohort of...2009; 106[47]: 770-6). Their medical-scientific ar...
(Date:12/3/2009)... 450 Deaths a day is still too many - s...k. , Atlanta, GA, Geneva,...3, 2009 -- The Measles Initiative announced today ...2000 and 2008, from an estimated 733 000 in 2000 t...perts warn of a resurgence in measles deaths if va...
(Date:12/3/2009)... Nutra Pharma will be conducting a webi...squo;s over-the-counter and prescription treatment... Plantation, FL (Vocus) Decem... biotechnology company that is developing treatmen...le Sclerosis (MS), has announced today that it wil...
(Date:12/3/2009)...ANTA ROSA, Calif., Dec. 3 Osseon T...eerable and curvable bone cement delivery needle) ...l) systems for percutaneous vertebral augmentation...alth Canada for marketing and clinical use in Cana... corresponds to FDA approval in the United States,...
(Date:12/3/2009)...AScientists at Boston Biomedical Research Institut...ound that combining two chemicals, one of which is...stroy a variety of protein structures known as amy...brain disorders such as Alzheimer,s, Huntington,s,... in the current issue of Nature Chemical Biology ...
Breaking Medicine News(10 mins):Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 2Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 3Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 4Health News:Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain 2Health News:Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain 3Health News:Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada 2Health News:Green tea chemical combined with another may hold promise for treatment of brain disorders 2
... Dr. Wayne Andersen to discuss weight management...uot; which is helping thousands maintain permanent...le-Dublin, Ohio (PRWEB) April 30, 2009 -- Dr. Wayn...three free seminars in the Westerville-Dublin area...
... G1G Travel Insurance and Student Funding Group ...l safely; Tuition Fee protection programs also add...se, CA (PRWEB) April 30, 2009 -- With a rise in in...udent Funding Group (StuFund) to offer newly creat...
...and, Ore.) A brief intervention program consisti...ne calls boosted by tenfold the number of women c...the findings of a Kaiser Permanente Center for Hea...intervention programs can be effective in increasi...
...illion in Total Revenues for the Quarter , , SAN ... Realty Trust, Inc. (NYSE: BMR ), a real estate ...to the Life Science Industry(R), today announced o...ter were $94.0 million, up 39.5% from $67.4 millio...
... VA,s Office of Research and Development is at th...eatments based on new knowledge about the role of ... to study genomics--the use of patients, individua...ed network of basic research and clinical applicat...
...ining the mechanism of a novel therapy that uses m... showed the treatment to be a promising alternativ...nial magnetic stimulation, or TMS. Study findings...ntrolled clinical study by Ohio State University M...
Other Medicine News:Health News:Physician and Author to Share Clinically Proven System for Permanent Weight Loss and Optimal Health in Westerville and Dublin, Ohio Areas 2Health News:New G1G Student Medical Insurance and Student Fee Protection Now on StuFund Web Site 2Health News:New G1G Student Medical Insurance and Student Fee Protection Now on StuFund Web Site 3Health News:Women 10 times more likely to do breast self-exams correctly with intervention, KP study finds 2Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 2Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 3Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 4Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 5Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 6Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 7Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 8Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 9Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 10Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 11Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 12Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 13Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 14Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 15Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 16Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 17Health News:Video: Turning Hope Into Reality - Genomics Research at the VA 2Health News:New therapy based on magnetic stimulation shows promise for non-drug treatment for migraine 2
(Date:12/3/2009)...TER, N.Y., Dec. 3 Virtua...er of quantitative imaging for clinical trials, an...ethod for 4D Reconstruction and Visualization" rec...pics, Vice President of Technology and Product Dev...ed that Japan has recognized the uniqueness of Vir...
(Date:12/3/2009)..., ROTTERDAM, The Netherlands, December 3 /PR...ny focused on the discovery and development of hum...y(TM) platform, today,announced the successful sec.... The Company raised an additional EUR 3.0 million...investors, Credit Agricole Private Equity and,VIB ...
(Date:12/2/2009)... NEW YORK, Dec. 2 Reportlinker.com...ailable in its catalogue: ,, Cardiac Pacemake...eportlinker.com/p0164335/Cardiac-Pacemakers---A-Wo...constitute a major segment in a rapidly expanding ...ac pacemakers market is characterized by relativel...
Breaking Medicine Technology:VirtualScopics Receives Issuance in Japan of Prominent Patent 2VirtualScopics Receives Issuance in Japan of Prominent Patent 3arGEN-X Concludes EUR 12.5 Million Series A Financing Round 2arGEN-X Concludes EUR 12.5 Million Series A Financing Round 3arGEN-X Concludes EUR 12.5 Million Series A Financing Round 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 2Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 3Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 6Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 8Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 9Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 10ATS Medical Announces Third Quarter 2009 Earnings Release Date and Conference Call 5713 1ATS Medical Announces Third Quarter 2009 Earnings Release Date and Conference Call 5713 2MedPlus Maintains Top Ranking in KLAS Industry Report 5710 1MedPlus Maintains Top Ranking in KLAS Industry Report 5710 2MedPlus Maintains Top Ranking in KLAS Industry Report 5710 3MedPlus Maintains Top Ranking in KLAS Industry Report 5710 4Reportlinker Adds Outsourcing Preclinical Studies to China 5707 1Reportlinker Adds Outsourcing Preclinical Studies to China 5707 2Reportlinker Adds Outsourcing Preclinical Studies to China 5707 3Reportlinker Adds Outsourcing Preclinical Studies to China 5707 4Reportlinker Adds Outsourcing Preclinical Studies to China 5707 5Reportlinker Adds Outsourcing Preclinical Studies to China 5707 6
...r Similar to Seven-Day in, Achieving Red Blood Cel...t in All MDS Patients Tested...Hematology (ASH) Meeting, ATLANTA, Dec. 11 Pharm...nterim data from a Phase 2 clinical trial,evaluati... Vidaza(R),(azacitidine for injection) that demons...
...city With Equivalent Complete Re...erapeutics, Inc.,(CTI) (Nasdaq and MTAX: CTIC) ann...II/III randomized study comparing CPOP-R to CHOP-R...essive non-Hodgkin,s lymphoma,(NHL) showed patient...(grade 3/4) toxicities including severe infection ...
Other Medicine Technology:MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 2MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 3MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 4MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 5MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 6Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 2Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 3Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 4Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 5
Multi Dop T1
EZ-Dop
...owerful automated system capable of handling any c...m 6 user-programmable test protocols to begin a fu...tests not included in the comprehensive list of au...ler, PVR and PPG instrument modes. Provides high f...
CD Horizon M10
Medicine Products: